WO2024005756 - ORAL DOSAGE FORMULATIONS COMPRISING EMPAGLIFLOZIN
National phase entry is expected:
Publication Number
WO/2024/005756
Publication Date
04.01.2024
International Application No.
PCT/TR2023/050592
International Filing Date
20.06.2023
Title **
[English]
ORAL DOSAGE FORMULATIONS COMPRISING EMPAGLIFLOZIN
[French]
FORMULATIONS POSOLOGIQUES ORALES COMPRENANT DE L'EMPAGLIFLOZINE
Applicants **
SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI
Inventors
GULER, Tolga
ARMUT, Merve
PEHLIVAN AKALIN, Nur
SUNEL, Fatih
Priority Data
2022/010736
29.06.2022
TR
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
Turkpatent
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1980 | |
| EPO | Filing, Examination, Granting | 9139 | |
| Japan | Filing, Examination, Granting | 2055 | |
| South Korea | Filing, Examination, Granting | 1824 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
19,738
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to oral dosage formulations comprising Empagliflozin or a pharmaceutically acceptable salt thereof and at least one filler wherein Empagliflozin or pharmaceutically acceptable salt has a d (0.9) particle size higher than 150 µm.[French]
La présente invention concerne des formulations posologiques orales comprenant de l'empagliflozine ou un sel pharmaceutiquement acceptable de celle-ci et au moins une charge ; l'empagliflozine ou le sel pharmaceutiquement acceptable ayant une taille de particule d (0,9) supérieure à 150 µm.